Literature DB >> 15194529

Issues surrounding therapeutic choices for hemophilia patients.

H Marijke Van den Berg.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15194529

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  2 in total

1.  Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

Authors:  Amy D Shapiro; Margaret V Ragni; Leonard A Valentino; Nigel S Key; Neil C Josephson; Jerry S Powell; Gregory Cheng; Arthur R Thompson; Jaya Goyal; Karen L Tubridy; Robert T Peters; Jennifer A Dumont; Donald Euwart; Lian Li; Bengt Hallén; Peter Gozzi; Alan J Bitonti; Haiyan Jiang; Alvin Luk; Glenn F Pierce
Journal:  Blood       Date:  2011-11-22       Impact factor: 22.113

2.  Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

Authors:  Jerry S Powell; Neil C Josephson; Doris Quon; Margaret V Ragni; Gregory Cheng; Ella Li; Haiyan Jiang; Lian Li; Jennifer A Dumont; Jaya Goyal; Xin Zhang; Jurg Sommer; Justin McCue; Margaret Barbetti; Alvin Luk; Glenn F Pierce
Journal:  Blood       Date:  2012-01-05       Impact factor: 22.113
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.